Shanghai, China - December 15, 2017 - The signing ceremony of WWF-Waters Strategic Cooperation Framework Memorandum Ceremony and the First Clinical Mass Spectrometry Technology Forum were successfully held in Shanghai Pinyin Medical Center on December 13, 2017. As the current One of the important components of the activity is that SENSIO and Waters Corporation signed a Memorandum of Strategic Cooperation Framework to jointly promote the application and development of mass spectrometry technology in the field of clinical medicine and conform to the global trend of precision medicine development. Conducting clinical mass spectrometry technology development and product marketing conducted in-depth discussions, Dr. Cheng Xiaoliang, chairman and president of Life Science and Medical Devices and Mr. Yu Xiaran, general manager of Waters China, respectively, signed on behalf of both companies. Chief Scientist, Dr. Trent Northen, Chief Medical Officer of Lawrence Berkeley National Laboratory and Head of Mass Spectrometry Technology Center, National Laboratory of Lawrence Berkeley, USA Dr. Guo Yan, Chief Financial Officer Dr. Yu Badat, Chief Data Officer Dr. Wang Yanzhong, Director of Market Development, Waters China Ms. Huang Jing, Dr. Tan Xiaojie, senior manager of health science market, attended and witnessed the signing ceremony .
Representatives from both parties attended the signing ceremony
After the signing ceremony, the first life medicine - Waters Clinical Mass Spectrometry Technology Forum was held immediately.The forum attracted a total of more than 50 guests attended, brought together from Shanghai Fudan University Zhongshan Hospital, Shanghai Jiao Tong University School of Medicine Ruijin Hospital, Shanghai Transportation Renji Hospital Affiliated to University Medical College, Changzheng Hospital of Naval Military Medical University, Tongji Hospital Affiliated to Tongji University, Shanghai United Family Hospital and other hospitals, as well as many investors, media and precision medical-related participants in the industry, Advances in clinical mass spectrometry under the wave of medicine.
Many experts, scholars and other precision medical industry guests attended the forum
During the academic exchange, many experts and scholars interpret the broad prospects of clinical mass spectrometry from multiple perspectives, such as technology platform, data mining and application scenarios, etc. Prof. Wang Yanzhong, Professor of Life Science College of King's University London and Director of Medical Big Data Center made a speech As a "paracetamol-induced dynamic prediction model of acute liver failure, the development and validation of the report," shared its experience as Europe's senior medical big data experts in the clinical translational medicine valuable experience.Subsequently, the United States Lawrence Berkeley National Laboratory Prof. Trent Northen, director of the National Center for Metabolomics and Mass Spectrometry, presented a report titled "The Relationship Between Molecular Change and Phenotype Through Comprehensive Metabolome and Proteomic Data Analysis" Based on the latest advances in multi-omics research, Dr TAM Xiao-jie, senior manager of Waters Health Sciences China, also presented a special report on the clinical application of MS in diabetes research.
Professor Wang Yanzhong, Professor of Life Sciences, King's University London, Director of Medical Big Data Center, shared the report
Trent Northen, Director, National Center for Metabolomics and Mass Spectrometry, Lawrence Berkeley National Laboratory, USA Share Report
Dr. Tan Xiaojie, senior manager of Waters Health Science China, shared the report
Through a platform of high-throughput mass spectrometry and clinical big data analysis, Pinnacle Medical has developed clinical mass spectrometry products that have independent intellectual property rights such as early diagnosis of cardiovascular disease and cancer screening. As a provider of clinical mass spectrometry solutions, And Beijing, Shanghai, Fuzhou, Wuhan, Hubei and other top three hospitals formed a strategic cooperation, the first clinical data-based cardiovascular disease risk marker diagnostic products released soon. Waters Corporation as the world's leading mass spectrometry equipment And technology providers dedicated to the design and manufacture of products and services such as Ultra Performance Liquid Chromatography, Chromatography and Mass Spectrometry systems. The two sides are committed to jointly promoting substantive industry-academia-industry collaboration and building a mass-spectrometry Technology exchange platform, in the majority of medical workers universal clinical mass spectrometry, clinical mass spectrometry professional and technical personnel on the road go hand in hand to create a better future, leading the development of clinical mass spectrometry industry.